The Prevent Cancer Foundation has developed a digital tool that can compare coverage of screening tests for breast, cervical, colorectal, lung, and prostate cancers across health insurance plans available in a specific state.
A review by the Prevent Cancer Foundation has found that insurance coverage of cancer screening tools varies based on the health plan. With this in mind, the Foundation has developed a digital tool that can compare coverage of screening tests for breast, cervical, colorectal, lung, and prostate cancers across health insurance plans available in a specific state.
The review, Cancer Screening: A Review of Guidelines and Insurance Coverage, summarizes current screening options and provides an overview of screening guidelines issued by the American Cancer Society, the National Comprehensive Cancer Network, and the US Preventive Services Task Force (USPSTF), in addition to a comparison of screening coverage by the 30 biggest health insurers in the United States. The following are a few key findings of this report:
While the USPSTF has assigned a D rating for using the PSA test to screen for prostate cancer, healthcare providers and health plans do not necessarily follow these recommendations. Carolyn R. Aldigé, president of the Prevent Cancer Foundation, told The American Journal of Managed Care (AJMC) in an e-mail that the Foundation’s annual meeting, Dialogue for Action, helps convene a variety of stakeholders to discuss such issues “and to provide information for individuals to engage in shared decision making with their providers.”
The study observed the following trend with breast cancer screening:
Screening Test
Plans Covering
Plans Not Covering
Plans Without Policy
Mammography (2D)
132
0
274
Breast Tomosynthesis (3D)
47
45
313
In an associated press release, the Prevent Cancer Foundation recommends that patients should discuss these inconsistencies, which could be a result of the guideline discrepancies across organizations. Aldigé told AJMC that the Foundation strives to educate and inform the public on the differences in guidelines and to clear any confusion that exists with using them.
“Effective cancer screening can lead to early detection of these potentially deadly diseases—but the variation between guidelines allows insurance companies to adopt cancer screening policies that may adversely affect patients’ access to preventive services,” Bernard Levin, MD, co-chair of the Prevent Cancer Foundation Scientific Review Panel, said in a statement.
The tool and the e-book can be accessed here.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More